*Contact Person:* Rhonda W. Stover or John B. Schupp, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7001, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12531. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* The committee will discuss new drug applications (NDA's) 20–977 (tablets) and 20–978 (oral solution) for abacavir sulfate (Ziagen, Glaxo Wellcome, Inc.) for the treatment of human immunodeficiency virus (HIV) infection.

*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by October 26, 1998. Oral presentations from the public will be scheduled between approximately 11 a.m. and 12 m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before October 26, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: October 2, 1998.

**Michael A. Friedman,**

*Deputy Commissioner for Operations.*

[FR Doc. 98–27082 Filed 10–8–98; 8:45 am]

**BILLING CODE 4160–01–F**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

### 1998 FDA Science Forum on Biotechnology: Advances, Applications, and Regulatory Challenges

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of meeting.

The Food and Drug Administration's (FDA's) Office of Science is announcing the following meeting: ''1998 FDA Science Forum on Biotechnology: Advances, Applications, and Regulatory Challenges.'' The meeting will bring FDA scientists together with representatives of industry, academia, government agencies, consumer groups, and the public to discuss the impact of the enormous advances in biotechnology on product development and regulation. The program will encompass bioengineered products, novel therapeutic and preventive approaches, diagnostics and detection methodologies, and safety and efficacy assessment.

*Date and Time*: The meeting will be held on December 8, 1998, 8:30 a.m. to 6 p.m., and December 9, 1998, 8:30 a.m. to 5 p.m.

*Location*: Washington Convention Center, rms. 30–33 (lower level) and Hall C (upper level), 900 Ninth St. NW., Washington, DC.

*Contact*: Susan A. Homire, Office of Science (HF–33), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–3366, e-mail ''shomire@bangate.fda.gov'' or American Association of Pharmaceutical Scientists 703–518–8429, e-mail ''meetings@aaps.org''.

*Registration*: December 8 and 9, 1998, 7 a.m. to 8:30 a.m. Registration and program information are available on the Internet at ''http://www.aaps.org/edumeet.html''. Attendance will be limited, therefore, interested parties are encouraged to register early.

If you need special accommodations due to a disability, please contact the American Association of Pharmaceutical Scientists at least 3 weeks in advance.

Dated: October 1, 1998.

**William K. Hubbard,**

*Associate Commissioner for Policy Coordination.*

[FR Doc. 98–27081 Filed 10–8–98; 8:45 am]

**BILLING CODE 4160–01–F**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

### National Consumer Forum; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of meeting.

The Food and Drug Administration (FDA) is announcing the following meeting: ''National Consumer Forum.'' This forum will provide an opportunity for consumers and older Americans to engage in an open dialogue with senior FDA officials on specific health concerns and consumer protection issues. These types of forums enable the agency to better determine the level of public interest in its current policies, as well as to promote a better understanding of consumer issues and concerns.

*Date and Time:* The meeting will be held on Monday, October 19, 1998, from 1 p.m. to 4 p.m.

*Location:* The meeting will be held at the Department of Health and Human Services, Hubert Humphrey Bldg., Great Hall, 200 Independence Ave. SW., Washington, DC.

*Contact:* Synthia E. Jenkins, Office of Consumer Affairs (HFE–40), Food and Drug Administration, 5600 Fishers Lane, 301–827–4412, FAX 301–443–9767.

*Registration:* Send registration information (including name, title, firm name, address, telephone, and fax number), to the contact person by October 15, 1998.

If you need special accommodations due to a disability, please contact Synthia E. Jenkins at least 7 days in advance.

*Transcripts:* Transcripts of the meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A–16, Rockville, MD 20857, approximately 15 working days after the meeting at a cost of 10 cents per page.

Dated: October 6, 1998.

**William K. Hubbard,**

*Associate Commissioner for Policy Coordination.*

[FR Doc. 98–27338 Filed 10–7–98; 12:38 pm]

**BILLING CODE 4160–01–F**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. 98N–0546]**

### Agency Information Collection Activities; Announcement of OMB Approval; Food Labeling Regulations

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Food Labeling Regulations (21 CFR Parts 101, 102, 104, and 105)'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA).

**FOR FURTHER INFORMATION CONTACT:** Margaret R. Schlosburg, Office of Information Resources Management (HFA–250), Food and Drug